Biomarin Pharmaceutical Inc. (BMRN)
NASDAQ:BMRN
Want to see BMRN full AI Analyst Report?
BMRN Stock Chart & Stats
$54.64
$0.93(1.37%)
At close: 4:00 PM EST
$54.64
$0.93(1.37%)
Day’s Range― - ―
52-Week Range$49.26 - $66.28
Previous CloseN/A
Volume465.01K
Average Volume (3M)2.23M
Market Cap
$10.31B
Enterprise Value$10.29B
Total Cash (Recent Filing)$2.22B
Total Debt (Recent Filing)$1.44B
Price to Earnings (P/E)39.2
Beta0.57
Next Earnings
Aug 04, 2026EPS Estimate
0.95Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.40
Shares Outstanding193,284,440
10 Day Avg. Volume2,874,955
30 Day Avg. Volume2,231,421
Financial Highlights & Ratios
PEG Ratio-1.71
Price to Book (P/B)1.87
Price to Sales (P/S)3.54
P/FCF Ratio15.72
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue3.17
Enterprise Value/Gross Profit4.18
Enterprise Value/Ebitda21.33
Forecast
1Y Price Target
$87.00Price Target Upside59.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)4.89
Revenue Forecast (FY)$3.90B
Bulls Say, Bears Say
Bulls Say
Portfolio Expansion Via Amicus AcquisitionThe Amicus deal materially broadens BioMarin’s rare-disease portfolio with established oral Galafold and Pompe assets plus a late-stage renal candidate. This diversification reduces dependence on any single product, increases commercial scale across lysosomal indications, and supports multi-year revenue runway and cross-selling in specialty channels.
Strong Operating And Free Cash FlowImproved and growing operating and free cash flow provides durable funding for R&D, clinical programs, and M&A without immediate reliance on equity raises. Strong cash generation also underpins the company’s ability to absorb one-time charges and invest in commercial expansion while supporting balance sheet resilience over coming quarters.
Voxzogo Pivotal Success Expands LabelA positive Phase 3 for hypochondroplasia and planned regulatory filings materially enlarge Voxzogo’s addressable pediatric growth market. Durable clinical and safety evidence plus potential approvals in new indications promise long-lived recurring revenues from chronic therapy use and strengthen product lifecycle value.
Bears Say
Margin Compression And Rising Operating CostsSustained margin pressure and elevated operating expenses weaken operating leverage. Higher R&D and commercial investments plus one-time manufacturing charges have reduced net and operating profitability, meaning the company must sustain above-trend revenue growth or realize synergies to restore historical margin levels and EPS conversion.
Increased Leverage From Acquisition FinancingThe acquisition’s asset-backed, covenant-heavy financing raises leverage and limits flexibility. Higher interest and covenant obligations increase vulnerability to revenue volatility or development setbacks, potentially forcing prioritization of deleveraging over discretionary R&D or commercial investments during adverse cycles.
Clinical And Development SetbacksMixed pivotal results and paused dosing in select trials underscore persistent clinical and regulatory risk. Negative or incomplete readouts can delay approvals, narrow label scope, and reduce peak sales potential for pipeline assets; this elevates execution risk and the need for additional trials or data to secure durable market access.
BioMarin Pharmaceutical News
BMRN FAQ
What was Biomarin Pharmaceutical Inc.’s price range in the past 12 months?
Biomarin Pharmaceutical Inc. lowest stock price was $49.26 and its highest was $66.28 in the past 12 months.
What is Biomarin Pharmaceutical Inc.’s market cap?
Biomarin Pharmaceutical Inc.’s market cap is $10.31B.
When is Biomarin Pharmaceutical Inc.’s upcoming earnings report date?
Biomarin Pharmaceutical Inc.’s upcoming earnings report date is Aug 04, 2026 which is in 60 days.
How were Biomarin Pharmaceutical Inc.’s earnings last quarter?
Biomarin Pharmaceutical Inc. released its earnings results on May 04, 2026. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.692 by $0.068.
Is Biomarin Pharmaceutical Inc. overvalued?
According to Wall Street analysts Biomarin Pharmaceutical Inc.’s price is currently Undervalued.
Does Biomarin Pharmaceutical Inc. pay dividends?
Biomarin Pharmaceutical Inc. does not currently pay dividends.
What is Biomarin Pharmaceutical Inc.’s EPS estimate?
Biomarin Pharmaceutical Inc.’s EPS estimate is 0.95.
How many shares outstanding does Biomarin Pharmaceutical Inc. have?
Biomarin Pharmaceutical Inc. has 193,284,440 shares outstanding.
What happened to Biomarin Pharmaceutical Inc.’s price movement after its last earnings report?
Biomarin Pharmaceutical Inc. reported an EPS of $0.76 in its last earnings report, beating expectations of $0.692. Following the earnings report the stock price went down -4.003%.
Which hedge fund is a major shareholder of Biomarin Pharmaceutical Inc.?
Currently, no hedge funds are holding shares in BMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$87.00 (59.22% Upside)
$87.00 (59.22% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.75%
12-Months-Change
Fundamentals
Return on Equity
4.41%
Trailing 12-Months
Asset Growth
20.20%
Trailing 12-Months
Company Description
Biomarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
BMRN Company Deck
BMRN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a predominantly positive outlook driven by the recent Amicus acquisition, upgraded 2026 revenue guidance (~20% total revenue growth and ~30% Enzyme Therapies growth at midpoint), strong underlying patient demand (Voxzogo patients +20% y/y; Enzyme Therapies +6% y/y), and multiple near‑term clinical catalysts. Near‑term softness in reported Q1 revenue, a $31M one‑time manufacturing charge, higher operating expenses and modest 2026 EPS dilution are notable headwinds, but management attributes much of the revenue softness to order timing and positions acquisition dilution as temporary with accretion expected within 12 months and substantial accretion in 2027. Overall, the positives (deal, guidance lift, patient growth, pipeline milestones) outweigh the one‑time charges and timing issues.View all BMRN earnings summariesBMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
BMRN Stock 12 Month Forecast
Average Price Target
$87.00
▲(59.22% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
PTC Therapeutics
―
Ultragenyx Pharmaceutical
―
Summit Therapeutics
―
Immunovant
―
Ownership Overview
0.32% Insiders
31.88% Mutual Funds
36.55% Other Institutional Investors
10.19% Public Companies and
Individual Investors